Authors: Xavier Durrmeyer, Shushanik Hovhannisyan, Yves Médard, Evelyne Jacqz-Aigrain, Fabrice Decobert, Jérome Barre, Corinne Alberti, Yannick Aujard, Claude Danan, Olivier Baud
DOI: 10.1371/journal.pone.0012329
Abstract Summary
Study finds genetic variants in CYP2C8/2C9 enzymes don’t predict ibuprofen treatment success for patent ductus arteriosus in extremely preterm infants. Instead, higher gestational age and non-Caucasian ethnicity were linked to better response rates. Results suggest ethnicity plays a key role in treatment variability, but genetic testing won’t help optimize dosing strategies.
Why Brain? 🧠
Study finds genetic variants in drug-metabolizing enzymes don’t predict ibuprofen effectiveness for closing heart defects in premature babies, but ethnicity and gestational age do matter.
The image is AI-generated for illustrative purposes only. Courtesy of Midjourney.
